Historical Valuation
AVITA Medical Inc (RCEL) is now in the Fair zone, suggesting that its current forward PS ratio of 1.28 is considered Fairly compared with the five-year average of -4.14. The fair price of AVITA Medical Inc (RCEL) is between 2.65 to 23.76 according to relative valuation methord.
Relative Value
Fair Zone
2.65-23.76
Current Price：3.28
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AVITA Medical Inc (RCEL) has a current Price-to-Book (P/B) ratio of -15.87. Compared to its 3-year average P/B ratio of 5.10 , the current P/B ratio is approximately -411.07% higher. Relative to its 5-year average P/B ratio of 4.39, the current P/B ratio is about -461.63% higher. AVITA Medical Inc (RCEL) has a Forward Free Cash Flow (FCF) yield of approximately -34.87%. Compared to its 3-year average FCF yield of -18.01%, the current FCF yield is approximately 93.62% lower. Relative to its 5-year average FCF yield of -14.27% , the current FCF yield is about 144.32% lower.
P/B
Median3y
5.10
Median5y
4.39
FCF Yield
Median3y
-18.01
Median5y
-14.27
Competitors Valuation Multiple
AI Analysis for RCEL
The average P/S ratio for RCEL competitors is 0.74, providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL.O) exhibits a P/S ratio of 1.28, which is 73.04% above the industry average. Given its robust revenue growth of -12.71%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RCEL
1Y
3Y
5Y
Market capitalization of RCEL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RCEL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RCEL currently overvalued or undervalued?
AVITA Medical Inc (RCEL) is now in the Fair zone, suggesting that its current forward PS ratio of 1.28 is considered Fairly compared with the five-year average of -4.14. The fair price of AVITA Medical Inc (RCEL) is between 2.65 to 23.76 according to relative valuation methord.
What is AVITA Medical Inc (RCEL) fair value?
RCEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AVITA Medical Inc (RCEL) is between 2.65 to 23.76 according to relative valuation methord.
How does RCEL's valuation metrics compare to the industry average?
The average P/S ratio for RCEL's competitors is 0.74, providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL) exhibits a P/S ratio of 1.28, which is 73.04% above the industry average. Given its robust revenue growth of -12.71%, this premium appears unsustainable.
What is the current P/B ratio for AVITA Medical Inc (RCEL) as of Jan 09 2026?
As of Jan 09 2026, AVITA Medical Inc (RCEL) has a P/B ratio of -15.87. This indicates that the market values RCEL at -15.87 times its book value.
What is the current FCF Yield for AVITA Medical Inc (RCEL) as of Jan 09 2026?
As of Jan 09 2026, AVITA Medical Inc (RCEL) has a FCF Yield of -34.87%. This means that for every dollar of AVITA Medical Inc’s market capitalization, the company generates -34.87 cents in free cash flow.
What is the current Forward P/E ratio for AVITA Medical Inc (RCEL) as of Jan 09 2026?
As of Jan 09 2026, AVITA Medical Inc (RCEL) has a Forward P/E ratio of -2.93. This means the market is willing to pay $-2.93 for every dollar of AVITA Medical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AVITA Medical Inc (RCEL) as of Jan 09 2026?
As of Jan 09 2026, AVITA Medical Inc (RCEL) has a Forward P/S ratio of 1.28. This means the market is valuing RCEL at $1.28 for every dollar of expected revenue over the next 12 months.